Imaging Liver Cancer Proliferation

肝癌增殖成像

• 批准号: 9082147
• 负责人: Zhenghong Lee
• 金额: $ 32.17万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-15 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9082147
• 关键词: Animal Model; Attention; Biodistribution; Biopsy; Cancer Etiology; Cell Proliferation; Cells; Cessation of life; Clinical; Companions; Cytidine Deaminase; Cytidine Deaminase Inhibitor; Cytosine; DNA; Data; Deamination; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Deoxyglucose; Development; Enzymes; Frequencies; Goals; Hepatic; Hepatic Tissue; Human; Image; Infection; Intestines; Label; Lesion; Liver; Lymphoid; Malignant neoplasm of liver; Measures; Metabolism; Methods; Modeling; Nucleosides; Operative Surgical Procedures; Organ; Patients; Pharmaceutical Preparations; Phosphotransferases; Positron-Emission Tomography; Primary carcinoma of the liver cells; Process; Proliferating; Radio; Recruitment Activity; Resistance; Schedule; Signal Transduction; T-Lymphocyte; TP53 gene; Testing; Tetrahydrouridine; Thymidine; Thymidine Kinase; Thymine; Tracer; United States; Validation; Viral hepatitis; Woodchuck; Work; analog; base; cancer therapy; chemotherapy; clinically relevant; design; effective therapy; gemcitabine; glucose uptake; imaging biomarker; novel; novel strategies; novel therapeutics; oncology; patient subsets; pre-clinical; predicting response; public health relevance; rapid growth; response; small molecule; treatment response; tripolyphosphate; tumor; uptake

 DESCRIPTION (provided by applicant): Hepatocellular Carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The main PET tracer currently used in oncology applications, 2-[18F]-fluoro-2-deoxy-D-glucose (FDG), has been shown to be ineffective for imaging HCC since many HCCs do not show differential FDG uptake comparing to the surrounding hepatic tissues. Identification of aggressive liver lesions with rapid growth (proliferation) with PET imaging also proves to be difficult since several thymidine analogs (all substrates of thymidine kinase (TK)) developed for proliferation imaging did not work well in the liver due mainly to glucuronidation, which leads to a high liver background uptake. We propose to investigate a newly developed tracer, 1-(2'-deoxy- 2'-[18F]-fluoro-β-D-arabinofuranosyl)cytosine ([18F]-FAC, a substrate more specific for deoxycytidine kinase (dCK) than for TK), which displays a lower liver background uptake. A modifier, tetrahydrouridine (THU, an inhibitor of cytidine deaminase (CDA)), will be added to suppress enzymatic activity of hepatic CDA and maintain FAC activity in the liver. We plan to establish this [18F]-FAC and THU combination for PET imaging of proliferation in HCC based on encouraging preliminary pre-clinical results and clinical biodistribution studies. Our central hypothesis is that FAC uptak is correlated with dCK-dependent proliferation in HCC; and [18F]-FAC-PET (THU) can be used to identify aggressive HCC and to predict response to dCK-dependent treatment. We will test this hypothesis via the following Specific Aims. Aim 1: To confirm the mechanism of [18F]-FAC uptake in HCC with a clinically relevant woodchuck model of HCC; Aim 2: To validate [18F]-FAC-PET (THU) uptake in patients with HCC; Aim 3: To explore the utility of [18F]-FAC-PET (THU) as a companion imaging biomarker for predicting the response to novel dCK-dependent treatment such as the new therapeutic combination of THU-decitabine.

 描述(申请人提供)：肝细胞癌是全球癌症死亡的第三大原因。目前用于肿瘤学应用的主要PET示踪剂2-[18F]-氟-2-脱氧-D-葡萄糖(FDG)已被证明对肝细胞癌的成像无效，因为许多肝细胞癌与周围的肝组织相比没有显示出不同的FDG摄取。用PET成像识别快速生长(增殖)的侵袭性肝脏病变也被证明是困难的，因为几种用于增殖成像的胸腺嘧啶核苷类似物(胸苷激酶(TK)的所有底物)在肝脏中不能很好地工作，这主要是由于葡萄糖醛酸化作用，这导致肝脏背景摄取较高。我们建议研究一种新开发的示踪剂1-(2‘-脱氧-2’-[18F]-氟-β-D-阿拉伯呋喃葡萄糖)胞嘧啶([18F]-FAC，一种对脱氧胞苷激酶比TK更特异的底物)，它显示出较低的肝脏背景摄取。将添加一种修饰剂四氢尿苷(清华，胞苷脱氨酶(CDA)的抑制剂)，以抑制肝脏CDA的酶活性，并保持肝脏中的FAC活性。我们计划在令人鼓舞的初步临床前结果和临床生物分布研究的基础上，建立这种[18F]-FAC和清华大学的组合，用于肝细胞癌增殖的PET成像。我们的中心假设是FAC uptak与DCK依赖的肝细胞癌的增殖相关；[18F]-FAC-PET(清华)可用于识别侵袭性的肝细胞癌并预测对DCK依赖的治疗的反应。我们将通过以下具体目标来检验这一假设。目的1：用临床相关的土拨鼠模型证实[18F]-FAC在肝细胞癌中的摄取机制；目的2：验证[18F]-FAC-PET(清华)在肝细胞癌患者中的摄取；目的3：探讨[18F]-FAC-PET(清华)作为预测DCK依赖新疗法(如清华-地西他滨联合治疗)疗效的辅助成像生物标志物的应用价值。